Ocugen Clinical Showcase Webcast Now Available
February 28 2024 - 8:00AM
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies and vaccines, today
announced that the Clinical Showcase webcast from the February 21,
2024 live event is now available in the Events & Presentations
section of the Ocugen website.
The showcase replay includes more detail on the Phase 3 study
design for OCU400, as well as market potential for this
first-in-class product candidate. The panel discussion offers
first-hand experience from an OCU400 Phase 1/2 clinical trial
patient with the RHO mutation who has completed 12 months of
therapy and lead investigator, Dr. Byron Lam, Professor of
Ophthalmology, Mark J. Daily, Endowed Chair in Ophthalmology at the
University of Miami. Dr. Lejla Vajzovic, Associate Professor of
Ophthalmology with Tenure, Director of Duke Vitreoretinal
Fellowship Program at Duke Eye Center and Duke University School of
Medicine, provides insight on the disease burden and unmet medical
need associated with retinitis pigmentosa. Finally, the inventor of
modifier gene therapy, Dr. Neena Haider, CEO & CSO Shifa
Precision, faculty at Harvard Medical School, gives commentary
throughout on the genesis of modifier gene therapy and how this
treatment approach has evolved from the lab into the clinic.
Please direct any questions related to the webcast to Tiffany
Hamilton, Head of Communications, at
Tiffany.Hamilton@ocugen.com.
About Ocugen, Inc.Ocugen, Inc. is a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies and vaccines that
improve health and offer hope for patients across the globe. We are
making an impact on patient’s lives through courageous
innovation—forging new scientific paths that harness our unique
intellectual and human capital. Our breakthrough modifier gene
therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more
at www.ocugen.com and follow us
on X and LinkedIn.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should,” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks, and
uncertainties that may cause actual events or results to differ
materially from our current expectations. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (SEC), including the risk
factors described in the section entitled “Risk Factors” in the
quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events, or otherwise, after the date of this
press release.
Contact:Tiffany HamiltonHead of
CommunicationsIR@ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024